Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M ; volume:13 ; number:1 ; day:21 ; month:12 ; year:2023 ; pages:1-5 ; date:12.2023
Blood cancer journal ; 13, Heft 1 (21.12.2023), 1-5, 12.2023
- Creator
-
Fandrei, David
Huynh, Tony
Sébert, Marie
Aguinaga, Lorea
Bisio, Valeria
Kim, Rathana
Clappier, Emmanuelle
Espéli, Marion
Balabanian, Karl
Moins-Teisserenc, Hélène
Toubert, Antoine
Dulphy, Nicolas
Fenaux, Pierre
Adès, Lionel
Zhao, Lin-Pierre
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-023-00965-w
- URN
-
urn:nbn:de:101:1-2024030613311846600048
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fandrei, David
- Huynh, Tony
- Sébert, Marie
- Aguinaga, Lorea
- Bisio, Valeria
- Kim, Rathana
- Clappier, Emmanuelle
- Espéli, Marion
- Balabanian, Karl
- Moins-Teisserenc, Hélène
- Toubert, Antoine
- Dulphy, Nicolas
- Fenaux, Pierre
- Adès, Lionel
- Zhao, Lin-Pierre
- SpringerLink (Online service)
Other Objects (12)
Myelodysplastic syndromes
Myelodysplastic syndromes
Epigenetic therapy in myelodysplastic syndromes
Myelodysplastic syndromes : with 87 tabeles
Bone marrow apoptosis in myelodysplastic syndromes
Emerging Therapies for the Myelodysplastic Syndromes
Myelodysplastic syndromes: Where do we stand?
Bone marrow apoptosis in myelodysplastic syndromes
Myelodysplastic syndromes current treatment algorithm 2018
Drug development in higher-risk myelodysplastic syndromes
Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
Myelodysplastic syndromes
Myelodysplastic syndromes
Epigenetic therapy in myelodysplastic syndromes
Myelodysplastic syndromes : with 87 tabeles
Bone marrow apoptosis in myelodysplastic syndromes
Emerging Therapies for the Myelodysplastic Syndromes
Myelodysplastic syndromes: Where do we stand?
Bone marrow apoptosis in myelodysplastic syndromes
Myelodysplastic syndromes current treatment algorithm 2018
Drug development in higher-risk myelodysplastic syndromes
Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
Myelodysplastic syndromes
Myelodysplastic syndromes
Epigenetic therapy in myelodysplastic syndromes
Myelodysplastic syndromes : with 87 tabeles
Bone marrow apoptosis in myelodysplastic syndromes
Emerging Therapies for the Myelodysplastic Syndromes
Myelodysplastic syndromes: Where do we stand?
Bone marrow apoptosis in myelodysplastic syndromes
Myelodysplastic syndromes current treatment algorithm 2018
Drug development in higher-risk myelodysplastic syndromes
Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes